RUNX1 RUNX1 mutation in a patient with myelodysplastic syndrome and decreased erythrocyte expression of blood group A antigen

摘要

BACKGROUND Loss of blood group ABO antigens on red blood cells (RBCs) is well known in patients with leukemias, and such decreased ABO expression has been reported to be strongly associated with hypermethylation of the ABO promoter. We investigated the underlying mechanism responsible for A‐antigen reduction on RBCs in a patient with myelodysplastic syndrome. STUDY DESIGN AND METHODS Genetic analysis of ABO was performed by PCR and sequencing using peripheral blood. RT‐PCR were carried out using cDNA prepared from total bone marrow (BM) cells. Bisulfite genomic sequencing was performed using genomic DNA from BM cells. Screening of somatic mutations was carried out using a targeted sequencing panel with genomic DNA from BM cells, followed by transient transfection assays. RESULTS Genetic analysis of ABO did not reveal any mutation in coding regions, splice sites, or regulatory regions. RT‐PCR demonstrated reduction of A ‐transcripts when the patient's RBCs were not agglutinated by anti‐A antibody and did not indicate any significant increase of alternative splicing products in the patient relative to the control. DNA methylation of the ABO promoter was not obvious in erythroid cells. Targeted sequencing identified somatic mutations in ASXL1 , EZH2 , RUNX1 , and WT1 . Experiments involving transient transfection into K562 cells showed that the expression of ABO was decreased by expression of the mutated RUNX1 . CONCLUSION Because the RUNX1 mutation encoded an abnormally elongated protein without a transactivation domain which could act as dominant negative inhibitor, this frame‐shift mutation in RUNX1 may be a genetic candidate contributing to A‐antigen loss on RBCs.